René Muttenzer
Nessuna posizione attualmente
Storia della carriera di René Muttenzer
Precedenti posizioni note di René Muttenzer
Società | Posizione | Inizio | Fine |
---|---|---|---|
ACINO HOLDING AG | Direttore/Membro del Consiglio | 17/11/2009 | 31/03/2012 |
NOVARTIS AG | Corporate Officer/Principal | - | - |
Posbelduf Biotech AG
Posbelduf Biotech AG Pharmaceuticals: MajorHealth Technology Molecular Health AG provides clinico-molecular informatic solutions. The firm’s approach allows doctors translate patient-specific molecular and genomic data, clinical history, and published scientific evidence into drug choices. The company was founded by Friedrich von Bohlen in 2004 and is headquartered in Basel, Switzerland. | Direttore/Membro del Consiglio | 03/03/2011 | - |
SPEXIS AG | Direttore/Membro del Consiglio | 17/11/2009 | - |
Formazione di René Muttenzer
University of Basel | Graduate Degree |
Statistiche
Distribuzione geografica
Svizzera | 6 |
Posizioni
Director/Board Member | 3 |
Graduate Degree | 1 |
Corporate Officer/Principal | 1 |
Settori
Health Technology | 5 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
SPEXIS AG | Health Technology |
NOVARTIS AG | Health Technology |
Aziende private | 2 |
---|---|
Acino International AG
Acino International AG Pharmaceuticals: MajorHealth Technology Acino International AG develops and manufactures pharmaceuticals in novel drug delivery form. The firm provides drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. It offers abelcet, bactiflox, clopacin, dolonica, hydronica, neurorubine, olfen and spasfon. The company was founded in 1836 and is headquartered in Zurich, Switzerland. | Health Technology |
Posbelduf Biotech AG
Posbelduf Biotech AG Pharmaceuticals: MajorHealth Technology Molecular Health AG provides clinico-molecular informatic solutions. The firm’s approach allows doctors translate patient-specific molecular and genomic data, clinical history, and published scientific evidence into drug choices. The company was founded by Friedrich von Bohlen in 2004 and is headquartered in Basel, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- René Muttenzer
- Esperienza